Rick Simpson Oil (RSO) f’Malta: Il-Gwida Kollha minn OilWell Cannabis

Għalfejn Qed Inħarsu lejn Malta

Minn darna f’Houston, Texas, qed nqisu kif l-okazzjoni madwar il-mediċina tal-cannabis evolviet madwar id-dinja. Malta—din il-gżira mediterranja rimarkabbli b’ storja sħiħa, komunitajiet magħquda, u approċċ proattiv lejn il-politika tal-kura tas-saħħa—ħarġet bħala post fejn in-nies qed jistaqsu l-mistoqsijiet t-tajbin dwar it-terapija tal-cannabinoids. Nafu li f’Malta, bħal f’Houston, il-familji qed jinavigaw deċiżjonijiet ta’ kura għall-kanċer, il-veterani qed jissoġraw bil-PTSD, il-pazjenti bil-uġijiet kroniċi qed jirċievu riċetti ineffettivi, u l-propjetarji tal-annimali domestiċi qed jiffaċċjaw dak il-mument ta’ tensjoni meta l-mediċina konvenzjonali tgħid li ma hemm xejn aktar li tista’ tagħmel.

Qed niktebu din il-gwida għaliex Malta tistħoqq l-istess edukazzjoni onesta, ibbażata fuq evidenza dwar RSO li għamlet OilWell Cannabis isem ta’ fiduċja fil-irba’ belt l-akbar fl-Amerika. Kemm jekk qed taqra dan mill-ibliet storiku ta’ Valletta, il-port mgħaġġel ta’ Sliema, jew il-kampanja kwieta ta’ Gozo, tistħoqq li tifhem x’inhu Rick Simpson Oil fil-fatt, liema xjenza tappoġġja, x’jista’ jagħmel u ma jistax jagħmel, u kif il-formuli moderni tagħna, ittestjati fil-lab, multi-cannabinoid isolvu l-problemi li RSO tradizzjonali qatt ma kien jista’.

Dan mhux kopia ta’ marketing miktuba minn aġenzija. Dan aħna—OilWell Cannabis—qed nitkellmu direttament miegħek f’Malta, qed naqsmu kollox tgħallimna minn għaxar snin ta’ xogħol ta’ formulazzjoni, seba’ karatteristiċi fuq ABC13, u l-esperjenza reali tal-għajnuna lil eluf ta’ pazjenti. Kull numru naqsmu, kull studju nisiltu, kull formula nippubblikaw huwa verifikabbli. M’aħniex hawn biex nbigħulek tama. Aħna qed ninkitbu biex nagħtuk l-informazzjoni li għandek bżonn biex tiddeċiedi x’hu tajjeb għalik u għal dawk li tħobb.

Fehim Rick Simpson Oil: L-Istorja Reali

Min Kien Rick Simpson?

Rick Simpson twieled fl-1949 f’Amherst, Nova Scotia, il-Kanada. M’għandux tabib, xjentist, jew riċerkatur mediku—kien injinier tal-enerġija u ħaddiem ta’ manutenzjoni, trabajant tal-collars blu li sab triqtu lejn il-mediċina tal-cannabis permezz ta’ sofferenza personali. Fl-1997, filwaqt li kien qed jaħdem f’sptar f’Moncton, Simpson waqeq mill-iscaffolding u sofra ġurija serja fl-ras. L-konsegwenzi inkludew tinnitus persistenti, sturdament, u sintomi ta’ wara konkużjoni li l-mediċina konvenzjonali naqset milli tissolva. Il-mediċini preskritti jew ma għenitx jew aggravaw l-affarijiet. Meta staqsie lit-tabib tiegħu dwar il-cannabis, it-talba ġiet rifjutata.

L-interess ta’ Simpson tjieb wara li tgħallem dwar studju tal-NIH imfaddal fl-1974 fil-Medical College of Virginia, fejn THC irrapporta li bil-mod kien iwaqqaf it-tkabbir tat-tumuri fil-grieden. Dak l-istudju—oriġinarjament maħsub biex juri l-ħsara—sar ir-referenza fundamentali ta’ Simpson, anke jekk is-sejħiet tiegħu qatt ma ġew replikati f’twissijiet kliniċi kkontrollati tal-kanċer tal-bniedem.

Il-mument pivotal ġie fl-2003. Simpson irrapporta li tliet bumps fuq idirgħu, idjagnostikati bħala karcinoma bażali tal-ġilda, sparixxew wara erbat ijiem ta’ applikazzjoni ta’ żejt tal-cannabis konċentrat direttament lejn il-leżjonijiet. L-ebda verifika medika indipendenti, konferma tal-bijopsija, jew segwitu kliniku ma ġew ippubblikati qatt. Din l-esperjenza personali—mittestjata bħala evidenza medika—sar l-istorja tal-orjin ta’ Rick Simpson Oil u niżlet moviment globali.

Għaliex Dan Huwa Importanti għal Malta: Ħafna f’Malta ġarrbu mumenti simili—meta s-sistema medika toffri l-ebda għażliet aktar, meta t-trattamenti jissoktaw, meta wieħed jingħad biex jipprepara għall-agħar. L-desperazzjoni li wasslet lil Simpson hija universali. Tgħaġġel lil pazjenti tal-kanċer Maltin jfittxu online fit-2 AM, tgħaġġel lil sofferenti tal-uġija kronika Gozitani jistaqsu lit-tobba tagħhom dwar alternattivi, tgħaġġel lil veterani Valletta jfittxu sollieħ mill-PTSD meta l-prodotti farmaċewtiċi naqsu mill-għalkemm. Fehim l-istorja ta’ Simpson ifisser fehim l-desperazzjoni li tagħmel RSO rilevanti—imma jfisser ukoll fehim id-differenza kritika bejn xhud personali u prova medika.

Il-Protokoll ta’ 60 Gramma: X’Ħaġa Rakkomanda Simpson fil-Fatt

Ir-rakkomandazzjoni ewlenija ta’ kura ta’ Simpson kienet protokoll ta’ 90 jum maħsub biex jipprovdi 60 gramma ta’ żejt tal-cannabis konċentrat. Eżattament dak li preskriva:

Ġimgħa 1: Ibda b’doża daqs nofs grajna tal-ross—madwar 10-15 mg ta’ żejt—tliet darbiet kuljum. Intake totali kuljum: 30-45 mg.

Ġimgħat 2-5: Iddubbla d-doża kull erba’ ijiem. Sal-ġimgħa ħamesa, laħħaq 1 gramma (1,000 mg) kuljum, maqsum fi tliet dożi ta’ madwar 333 mg kull waħda.

Ġimgħat 5-12: Żomm 1 gramma kuljum sakemm il-60 gramma kollha jkunu konżumati.

Simpson irrakkomanda amministrazzjoni orali (sottolingwali jew inħuta) bħala primarja, applikazzjoni topika għal kundizzjonijiet tal-ġilda, u aċċetta inhalazzjoni għal sollieħ immedjat tas-sintomi imma mhux bħala t-trattament prinċipali.

Kuntest Kritiku għal Malta: Fil-livell ta’ dożaġġ massimu, RSO tradizzjonali ipprovda madwar 600-900 mg ta’ delta-9 THC kuljum. Din id-doża teċċedi kull ħaġa studjata f’twissijiet kliniċi kkontrollati. Il-mediċina sintetika ta’ THC approvata mill-FDA, dronabinol, normalment titqies bħala 2.5-20 mg kuljum. Il-konsum ta’ 600-900 mg kuljum fih riskji serji: intossikazzjoni severa, ħsara, ansjetà, paniku, takikardija, ipotensjoni, u użu tal-cannabis. Għal pazjenti Maltin li diġà jiffaċċjaw kundizzjonijiet mediċi kumplessi, dawn ir-riskji ma jistgħux jiġu injorati.

X’Kien RSO Tradizzjonali Fil-Fatt

Rick Simpson Oil tradizzjonali kien:

• Materjal tas-sors: Tant wieħed ta’ razza high-THC indika, mhux standardizzat
• Solvent ta’ estrazzjoni: Naphtha (a bażi ta’ petrolju) jew alkoħol isopropyl 99%—la l-ieħor ta’ grad tal-ikel
• Proċess: Backet, solvent, agitazzjoni, filtrazzjoni, evaporazzjoni tal-cooker tal-ross, ħżin f’siringa
• Dehra: Kważi sewda, spissa, żejt bħaż-żift b’riħ ta’ solvent residwu
• Profil kannabinoid: 60-90% delta-9 THC, dekarbossilata kompletament, l-ebda kontroll tar-relazzjoni, qatt ma ġiet verifikata fil-lab
• Terpeni: Effettivament iddistrutti mis-solvent u s-sħana
• Standardizzazzjoni: Xejn—kull batch differenti
• Ttestjar: L-ebda COAs, l-ebda skrinjar ta’ kontaminanti
• Sikurezza: Riskju signifikanti ta’ solvent residwu, speċjalment minn naphtha li jista’ jkun fih benzene, toluene, u karcinoġeni oħra

Il-Konnessjoni ma’ Malta: Jekk int f’Malta u rajt prodotti “RSO” f’diskussjonijiet lokali jew forums online, jistgħu jkunu ftit simili għal dak li Simpson fil-fatt għamel. Ħafna prodotti moderni imsejħa “RSO” huma sempliċiment estratti full-spectrum f’siringi—varjabbli, mhux ttestjati, u potenzjalment mhux sikuri. Fehim x’kien RSO tradizzjonali fil-fatt jgħinek tevalwa x’qed jinbiegħ f’Malta llum.

OilWell Cannabis: Il-Fondazzjoni Tagħna

Mill-McAllen sa Malta: Storja ta’ Sopravivenza u Innovazzjoni

OilWell Cannabis twaqqfet minn Colin Valencia f’Houston, Texas. Iżda l-istorja ta’ Colin ma tibdiex f’Houston—tibdiex f’McAllen, Texas, waħda mir-reġjuni l-iktar imfixkla ekonomikament u perikolużi tul il-fruntiera bejn l-Istati Uniti u l-Messiku. Zona McAllen-Reynosa, magħrufa bħala l-Borderplex, hija post fejn il-faqar huwa pervasiv, il-vjolenza tal-kartell hija realtà kuljum, u l-opportunitajiet huma rari barra mir-retail u l-kura tas-saħħa.

Colin kbir jitgħallem jaħdem f’dan l-ambjent—ittrasporta oġġetti tul il-fruntiera, jinaviga perikli li ħafna nies qatt ma jiffaċċjaw. Ħafna mill-ħbieb t-tajba tiegħu nqatelu jew huma fil-ħabs minħabba l-perikli assoċjati. Ffaċċja kull forma ta’ vjolenza immaginabbli, kemm fit-toroq kif ukoll tul il-fruntiera. Sal-età ta’ sittax, b’xi mod jew ieħor, kellu jitlaq mid-dar għal dejjem.

Minkejja dawn l-isfidi, Colin ma waqax fil-pjati l-aktar dlamanti. Agħżel il-cannabis—mhux bħala ħarba rikreattiva, imma bħala pjanta li kien jemmen tista’ tgħin lin-nies. Kber fid-dinja tradizzjonali tal-cannabis ħafna qabel il-legalizzazzjoni, jitgħallem il-pjanta intimament filwaqt li jopera fl-isbaterija. Matul iż-żmien, għadda minn dawk l-investimenti riskjuż għal binjien ta’ negozju legali u leġittimu.

Wara, Colin sar inginier tal-software format u għamel xogħol ta’ żvilupp għal Baylor College of Medicine, waħda mill-istituzzjonijiet mediċi l-aktar prestiġjużi fil-Texas Medical Center. Dak il-kombinazzjoni—għarfien fond tal-pjanta tal-cannabis flimkien ma’ preċiżjoni teknika ta’ grad mediku—jiddefinixxi kollox li nagħmlu f’OilWell.

Għaliex Malta Għandha Tinkwetak: Malta għandha komunitajiet tagħha stess stmati mill-istimi riġidi ekonomiċi, dinamiki tal-fruntiera (għalkemm differenti minn Texas), u sfidi sistematiċi. Kemm jekk int Bormla, Żejtun, jew Victoria, Gozo, tifhem li l-innovazzjoni reali ħafna drabi tiġi minn nies li ġarrbu sofferenza reali. L-isfond ta’ Colin mhuwiex storja korporattiva—huwa storja ta’ sopravivenza li tinforma għaliex napprezzaw l-aċċessibbiltà, it-trasparenza, u l-integrità aktar minn kollox.

Bentley: Il-Kelb li Beda Kollox

L-istorja tal-orjini tal-kumpanija tagħna tibda ma’ kelb jismu Bentley. Bentley kien aktar minn annimal domustiku—kien familja, il-kumpanju li waqaf ma’ Colin tul l-iktar ħinijiet iebsa. Meta Bentley marid serjament, it-tobba veterinarji tawlu d-deċiżjoni li l-ebda sid annimal ma jixtieq jisma’: it-eutanasja kienet l-unika għażla umana. Bentley kien paralizzat fir-rieglejn ta’ warajh. Qalulhom li l-mediċini tal-uġigħ kienet tiddistruġġi l-organi interni tiegħu, tagħmel aktar sofferenza. Il-għażla kienet dewmien umli uddul jew qtil immedjat ta’ ħniena.

Iżda it-tluq minn Bentley ma kienx għażla. F’tiftix disprat għal alternattivi, Colin sab CBD—permezz ta’ mistoqsija li bdiet kollox. Ħaddiem ta’ salvataġġ jismu Jessica staqsiet: “Int transportajt kemm tonn ta’ weed u qatt ma smajt dwar CBD?”

Colin kellu esperjenza tal-cannabis, iżda kienet rikreattiva. Il-mistoqsija ta’ Jessica esponiet spott blind li kien se jsir missjoni.

Ddeterminat biex isalva Bentley, Colin tgħallem joħloq pasta golden CBD—formula ta’ kannabinoidi speċjalizzata għall-annimali domestiċi. Mhux kura, imdaħħla. U dik l- tama pprovdiet xi ħaġa li l-mediċina veterinarja qalet impossibbli: Bentley qam. Mmur lejn Colin u ġiebulu l-ballun tiegħu biex jilgħab. Minn paralizzat u jiffaċċa eutanasja sal-ġibda tal-ballun tiegħu. Dan ma kienx placebo—il-klieb ma jirrispondawx għal placebo. Din kienet mediċina tal-kannabinoidi tagħmel dak li l-prodotti farmaċewtiċi ma setgħux.

Bentley għex għaxar snin oħra, u miet b’mod naturali fl-età ta’ għoxrin. Tul dawk is-snin, Colin żviluppa formuli ta’ cannabis speċjalizzati għal kull kundizzjoni relatata mal-età li Bentley faċċa:

• Ħsad newrodeġenerattiv → Proprjetajiet newroproteettivi tal-CBG u PPARγ agonism tal-THCa għall-protezzjoni tal-ċelluli tal-moħħ
• Demenzja → Rwol tal-CBC fin-newrogenesi
• Glaucoma → CB1 agonism tal-THC għat-tnaqqis tal-pressjoni intraokulari
• Artrite paralizzanti → Approċċi multi-pathway kontra l-infjammazzjoni jużaw CBD, CBG, THCa, u beta-kariofilene jaħdmu flimkien permezz ta’ sistemi ta’ riċetturi differenti simultanjament

Kannabinoids singoli ma kinux biżżejjed. Il-kundizzjonijevolvi ta’ Bentley teħtieġ sinerġija multi-kannabinoid. Il-CBD biss ma setax jindirizza newrodeġenerazzjoni, demenzja, glaucoma, u artrite simultanjament. Kannabinoids minori bħal CBG, CBN, u CBC saru kritiċi meta Bentley żied fl-età. Preċiżjoni farmaċewtika kienet importanti—ħajjet Bentley kienet tiddependi fuq l-eżattezza tal-formula, mhux fuq il-guesswork.

Għall-Propjetarji tal-Annimali Domestiċi f’Malta: Jekk int f’Malta u ġarrbte dijanjosi simili għall-kelb jew il-qattus għażież tiegħek—forsi terrier Malti, kelb tal-faraoh, jew salvataġġ minn Gozo—taf dik id-desperazzjoni. L-istorja ta’ Bentley hija għaliex nippubblikaw ir-riċetta tal-pasta golden CBD tagħna b’xejn:

Riċetta tal-Pasta Golden CBD għall-Annimali Domestiċi (Open-Source)

Ingredjenti:

• 1/2 tazza turmeric powder organiku
• 1 tazza ilma
• 1/3 tazza żejt tal-kokos (mhux raffinat, organiku)
• 1-2 ċkupijiet bżar iswed moħru (kritiku għall-assorbiment)
• Żejt CBD (id-dożaġġ tiddependi mid-daqs tal-annimal domustiku; konsulta veterinarju)

Istruzzjonijiet:

1. Immixa t-turmeric u l-ilma f’taġen fuq sħana baxja, iħawwad kontinwament sakemm jiġi pasta spessa (7-10 minuti)
2. Żid iż-żejt tal-kokos u l-bżar iswed, iħawwad sakemm jinħoloq b’mod sħiħ
3. Ħalli jikkes, imbagħad ittrasferixxi f’jar u aħżen fil-fridge għal ġimgħatejn
4. Żid żejt CBD għal kull porzjon qabel ma tużah

Għal Malta: Din ir-riċetta tuża ingredjenti li jinsabu f’kull ħanut tal-ikel tal-Malti jew supermarché. Jekk int Valletta, tista’ ssib turmeric organiku u żejt tal-kokos f’Arkadia Foodstore jew Good Earth. Il-bżar iswed huwa kritiku—huwa dak li jagħmel it-turmeric biodisponibbli. Din hija l-formula eżatta li salva Bentley, u qed nagħtuha lil Malta b’xejn għaliex dak li jfisser OilWell.

Il-Battalja Personalina: PTSD u Tluq mill-Benzo

Colin jaf ukoll id-dipendenza farmaċewtika personalment. Ssielet mal-PTSD u mal-vizzju tal-benzodiazepina—speċifikament Xanax. Meta iddeċieda li jorbot il-ħut, għamel kallu, proċess notorjament diffiċli u perikoluż, juża l-għarfien tal-kannabinoidi li żviluppa biex iżomm Bentley ħaj.

Il-formula tal-Peace Gummies li saret prodott OilWell inħolqot tul esperimenti f’nofsillejl filwaqt li ġġieled bit-tluq mill-benzo. Biex jiżgura sollieħ malajr, noffru wkoll Peace Gummies fi forma ta’ vape, li Colin juża personalment biex immaniġġja in-nuqqas ta’ ħajja u PTSD sever. Dan mhux għarfien teorettiku. Colin għex dak li jgħixu pazjenti RSO: desperazzjoni għal sollieħ, prodotti farmaċewtiċi li naqsu, l-iskoperta li l-kannabinoidi jaħdmu meta l-pills ma jaħdmux.

Naslu lejn il-Veterani u s-Sopravviventi tat-Trauma ta’ Malta: Malta għandha storja militari kbira u komunità ta’ veterani li tistħoqq l-appoġġ. Kemm jekk int veterani ta’ missjonijiet ta’ paċi internazzjonali jew xi ħadd li jaħdem bit-trauma minn kwalunkwe sors, l-esperjenza personali ta’ Colin ma’ PTSD u tluq mill-benzo tagħmel il-prodotti tagħna rilevanti għall-vjaġġ tiegħek. Nifhmu x’inhu bħal meta s-sistema konvenzjonali tfalli.

Riżonoxximent tal-Midja Mainstream: Seba’ Karatteristiċi ABC13

Bejn Settembru 2019 u April 2023, ABC13 Houston (KTRK) ffaxxat lil Colin u OilWell f’seba’ segments tax-xandir komprensivi. Ħames riporters differenti fitxuh tul dawk is-snin: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, u kittieba tal-persunal KTRK. L-ebda operatur tal-cannabis Houston ieħor ma jidher b’dik il-frekwenza jew wisa’.

X’Tifisser Dan għal Malta: Meta affiljat ABC ta’ suq ewlieni jagħżel b’mod ripetut kumpanija waħda bħala l-espert prinċipali tiegħu, ifisser li dik il-kumpanija kisbet kredibilità permezz ta’ konsistenza, għarfien, u azzjoni tal-komunità. Dawn ma kienux reklami mħallsa—kienu deċiżjonijiet editorjali magħmula minn ġurnalisti li koprew in-negozju, il-liġi, il-mediċina, is-saħħa tal-komunità, u l-politika. Għal qarrejja Maltin, din hija prova verifikata indipendentement li OilWell topera b’livell ta’ trasparenza u integrità li ħafna kumpaniji tal-cannabis ma jistgħux jaqblu.

Hawn x’dokumenta ABC13:

15 ta’ Settembru 2019 — “In-negozji tal-CBD fl-Texas qed jikbru”
Kwotazzjoni fundamentali ta’ Colin: “Mhux qed nipprova nbigħulek snake oil. Mhux qed nipprova nbigħulek tama, imma hemm riċerka biżżejjed hemmhekk li n-nies għandhom bżonn jafu u jippruvaw u jkollhom l-aħjar verżjoni possibbli biex ibagħtu l-opinjonijiet tagħhom off, biex jagħtuh xorti ġusta jekk huwa tajjeb jew ħażin għalihom.”

Din il-kwotazzjoni mill-2019 hi l-ġemma ta’ kollox li nkunu. Tiġbor għaliex nippubblikaw il-formuli tagħna, għaliex nisiltu r-riċerka, u għaliex nirrifjuta li nagħmlu talbiet mhux appoġġjati.

22 ta’ Marzu 2021 — “Intraprenur joħloq negozju dirett-to-konsumatur”
Il-framing ta’ terapija ta’ Colin: “In-nies jaħsbu li kulħadd irid jisbaħ biss u huwa dwar it-tiħġiġ u affarijiet bħal dawn, u m’hemm xejn ħażin f’dan. Imma din hija verżjoni differenti ta’ terapija, u n-nies qed ifittxu affarijiet biex jgħinuhom bil-uġigġ reali. L-uġigġ jiġi f’ħafna forom differenti.”

24 ta’ Mejju 2021 — “X’inhu Delta-8 THC”
Skambju ta’ Steve Campion:
Campion: “Għaliex xi ħadd jixtieq jisgħuha?”
Colin: “M’għandix jiswa jekk hu ħażin li tgħid li tisbaħ minnha. Forsi trid tisbaħ.”

Din l-onestà mhux ċensurata fit-televiżjoni mainstream—ABC13 xeġġlet il-parola mhux xierqa—turi l-impenn tagħna li ngħidu l-verità anke meta tkun sfortevoli.

20 ta’Awwissu 2021 — “Ħanut CBD Houston jagħti prodotti b’xejn għall-vaċċin COVID”
Tgħamix 1,000 caviar pre-rolls (madwar $35,000 f’prodott) biex inkoraġġixxu l-vaċċinazzjoni COVID. Kkoordinnajna mal-Belt ta’ Houston, bl-ebda aġenda politika, għaliex is-saħħa tal-komunità hija aktar importanti mill-profitt.

19 ta’ Ottubru 2021 — “Il-Florida ta’ Texas fuq Delta-8”
Meta t-Texas reklassifikat Delta-8 bħala Skeda I f’lejl, aħna proattivament neħħejnha l-prodotti kollha mis-shelves tagħna. Colin ħabbar lil operaturi oħra li kienu qed ibagħtu bla ma jafu dak li sar narkotika Skeda I: “Huwa diżappuntanti, imma mhu se nitlef lill-klijenti tiegħi u n-negozji se jkollhom bżonn l-għarfien tagħna dwar kif ikomplu jibbenefikaw fl-industrija.” Sorġejna telfa massiva ta’ dħul biex noperaw b’etika.

7 ta’ Ottubru 2022 — “Il-perduna tal-marijuana ta’ Biden”
Din il-karatteristika wriet l-istorja tal-konvizzjoni personali ta’ Colin bil-marijuana: “Tiffaċċja sfidi mal-akkomodazzjoni, self, u banking, nifs dwar kollox. Nixtieq nara nies ma jweġġġux aktar għal din.” Dan il-palat personali jagħmel kull kwotazzjoni oħra aktar qawwija. Colin mhuwiex minn barra li jibbenefika mill-cannabis—huwa ħadd li għex il-konsegwenzi u banna negozju legali biex jipprova li l-industrija tista’ topera bl-integrità.

21 ta’ April 2023 — “L-industrija tal-marijuana qed tkreattivi”
Il-framing ta’ Rinaxximent ta’ Colin: “Il-mument issa huwa tassew pjuttost – bħal Rinaxximent – ħin pjuttost importanti li għandu jiġi gawdut issa.”

Għal Malta, dan ir-rekord tal-midja jipprova li OilWell ġie vettjat mill-ġurnalizzmu indipendenti tul erba’ snin. Meta taqra dwar il-prodotti tagħna, mhux qed taqra dwar kopia ta’ marketing—qed taqra dwar kumpanija li l-midja ewlenija tafda bħala sors ta’ għarfien.

L-Xjenza Wara l-Formuli Tagħna

Approċċ Ibbażat fuq L-Evidenza: Dak Li Nafu vs Dak Li Mhux

Bnejna dan id-dokument bl-użu ta’ ġerarkija formali tal-evidenza: evidenza klinika tal-bniedem l-ewwel, imbagħad reviżjonijiet sistematiċi, imbagħad sommarji istituzzjonali, imbagħad letteratura preklinika. Il-popolazzjoni edukata ta’ Malta—kemm jekk int professjonist tal-kura tas-saħħa f’Gozo, riċerkatur fl-Università ta’ Malta, jew sempliċement xi ħadd li japprezza r-rigor xjentifiku—tistħoqq din il-livell ta’ trasparenza.

Importanti għal Malta: Il-bażi tal-evidenza tal-kannabinoids m’hijiex imqassma bl-ugwaljanza. Għandhom l-iktar data tal-bniedem b’saħħitha l-CBD u d-delta-9 THC; d-delta-8 THC, THCa, CBG, CBN, CBC, u ħafna terpenes jiddependu aktar fuq reviżjonijiet, xogħol fuq l-annimali, u farmakoloġija preklinika. Qatt ma nippretendu mod ieħor.

Profili Kannabinoid: Il-Ħdax-il Kompound fil-Formula Tagħna

CBD (Cannabidiol) — 4,500mg f’Żejt Sottolingwali

L-Evidenza L-Aħjar Appoġġjata:

• Trastorni tal-epilessija: Il-CBD purifikat għandu l-iktar evidenza ċara tal-bniedem, bl-approvazzjoni tal-FDA għal xi epilessiji rari [1][2]
• Ansjetà: Reviżjoni sistematika tal-2024 ta’ 316 parteċipant sab sinjal anssjiolittiku sinifikanti, għalkemm l-awturi jisħqu li hemm bżonn aktar provi [3]
• Uġigġ: Reviżjoni tal-2024 sab riżultati premettenti imma eteroġenei, bil-kwalità tal-prova tgħaddi l-kunfidenza [4]
• Nemus: Reviżjoni tal-2023 sab li l-letteratura hija metodoloġikament dgħajfa, b’ftit evalwazzjonijiet tal-nemus oġġettivi [5]

Kunsiderazzjonijiet ta’ Sikurezza:
Reviżjoni sistematika tal-2023 sab sinjali reali għal elevatezza tal-enzimi tal-fwied u possibbli ġurija tal-fwied indotta mid-droga, speċjalment rilevanti għal prodotti orali konċentrati u settings ta’ polifarmapija [6]. NCCIH wkoll tqajjem dijarrea, għajjien, bidliet fl-aptit, effetti tal-mood, u interazzjonijiet droga-droga [1].

Għal Malta: Jekk int f’Malta tiffaċċja uġigġ kroniku, ansjetà, jew problemi tan-nemus—forsi bħala alternattiva għall-benzodiazepini jew opioids—il-CBD huwa l-għażla l-iktar studjata mhux intossikanti. Imma anke hawnhekk, l-evidenza qawwija hi kkuncentrata f’indikazzjonijiet speċifiċi milli f’pretensjonijiet ta’ wellness wiesgħa.

CBG (Cannabigerol) — 3,000mg f’Żejt Sottolingwali

Profil tal-Evidenza: Iħawwel aktar fuq livell ta’ reviżjoni u prekliniku; l-evidenza tal-bniedem għadha rari [7][8].

Farmakoloġija: Il-CBG huwa l-prekursur bijo-sintetiku għall-kannabinoids ewlenin, jinteraġixxi ma’ riċetturi kannabinoids, riċetturi alfa-2 adrenergici, u signal relatat ma’ 5-HT1A—meġġanikament interessanti imma mhux stabbilit klinikament [7].

Oqsma ta’ Riċerka: Ir-reviżjonijiet jiddiskutu possibbli rilevanza għal trastorni newroloġiċi, marda tal-musrana infjammatorja, u attività antibatterjali, imma dawn huma l-aktar ipoteżi mmexxija mill-farmakoloġija [7][8].

Twissija: Reviżjoni tal-2021 tiddikjara espliċitament li CBG qed jinbiegħ kummerċjalment filwaqt li l-bażi tal-evidenza għadha dgħajfa [7].

Għal Malta: Il-CBG huwa kannabinoid minoru promettenti b’validazzjoni klinika limitata. Inkludieh f’livelli sostanziali għaliex l-xjenza preklinika hija kompelliċenti, imma aħna trasparenti dwar il-vojt tal-evidenza.

Delta-8 THC — 6,000mg f’Żejt Sottolingwali

Profil tal-Evidenza: Farmaċoloġikament rilevanti, psikotropiku, u ħafna inqas karatterizzat klinikament mill-delta-9 THC [9]-[11].

Farmakoloġija Komparattiva: Reviżjoni tal-2022 waslet għall-konklużjoni li d-delta-8 u d-delta-9 THC għandhom imġiba farmakokinetika largament simili. Id-delta-8 huwa agonist parzjali CB1 b’attività kannabimimetika, iżda jidher inqas qawwi mill-delta-9, probabilment minħabba affinità CB2 aktar dgħajfa [9].

Kunsiderazzjonijiet tas-Saħħa Pubblika: Reviżjoni tal-2023 ta’ skoping sab li l-bażi tal-evidenza hija ddominata minn studji fuq l-annimali, kimika tal-prodott, u tħassib tas-saħħa pubblika milli twissijiet b’saħħa qawwija tal-bniedem, b’reports ta’ konsegwenzi avversi [10].

Kuntest ta’ Manifattura: L-interess kummerċjali fid-delta-8 huwa marbut ma’ stabilità akbar u sintesi aktar faċli relatata ma’ livelli tal-pjanta naturalment skarsi, li jqajjem tħassib dwar prodott-byproduct u ttestjar tal-lab [11].

Għal Malta: Id-delta-8 THC huwa psikotropiku u għandu jiġi ttrattat bħala analogu ta’ THC b’attività farmaċoloġika reali imma kkjarifikazzjoni sikura tal-bniedem mhux kompluta. Il-prodott tagħna fih delta-8 sostanzjali—6,000 mg—li jagħmluħ ħafna aktar qawwi mill-prodotti tal-ħemp tipiċi mibjugħa f’Malta.

THCa (Acid Tetraidrokanabinoliku) — 1,500mg f’Żejt Sottolingwali

Profil tal-Evidenza: Importanti kimikament u formulazzjoni, iżda għadha baxxa fuq evidenza terapewtika diretta tal-bniedem [12].

X’Inhu: Il-THCa huwa l-prekursur aċiduż tal-THC u jista’ jirrappreżenta sehem kbir tal-kontenut relatat ma’ THC fil-materjal tal-pjanta mhux ipproċessat. Il-kwistjoni ewlenija hi li l-THCa tiddikarbossalat għal THC tul is-sħana u tista’ tinbidel matul iż-żmien tul ħażna u proċessar [12].

Psikotropaċità: Il-THCa innifsu ma jipproduċix effetti psikotropiċi, imma din id-distinzjoni tibqa’ biss jekk il-molekola tibqa’ fil-formola aċiduża tagħha u ma tkunx dekarbossilata sostanzjalment [12].

Status tar-Riċerka: Il-letteratura in vitro u fuq l-irgus tissuġġerixxi possibilitajiet kontra l-infjammazzjoni, immunomodulatorja, newroprotezzjoni, u antineoplastika, iżda dawn mhumiex ekwivalenti għal riżultati umani stabbiliti [12].

Għal Malta: Il-THCa hija l-“killer feature” tal-prodott tagħna. Tista’ tużaha mhux ipproċessata (mhux psikotropika) għal benefiċċji kontra l-infjammazzjoni tul il-jum, jew tiddikarbossalaha d-dar biex issir ~1,315 mg ta’ delta-9 THC biex tikseb potenza psikotropika sħiħa—legalment, għaliex il-konverżjoni tiġri wara l-xiri. Dan jagħti lill-pazjenti Maltin kontroll li RSO tradizzjonali qatt ma offra.

Delta-9 THC — 90mg f’Żejt Sottolingwali

Profil tal-Evidenza: L-evidenza l-aqwa tal-bniedem tal-kannabinoidi psikotropiċi, imma wkoll l-aktar piż ċar ta’ effetti avversi [1][13]-[15].

L-Użi L-Aqwa Appoġġjati: NCCIH tidjentifika rilevanza għal nauseu/qerda relatata ma’ kimoterapija, aptit/telf ta’ piż f’HIV/AIDS, u xi riżultati relatati ma’ MS/uġigġ [1].

Evidenza tal-Uġigġ: Reviżjoni sistematika tal-2022 sab li prodotti b’ THC għoli jistgħu jipprovdu benefiċju ta’ uġigġ fit-tul qasir imma żdiedu stordiment, sedazzjoni, nauseu, u t-twaqqif tat-trattament [13].

Riskju tas-Saħħa Mentali: Reviżjoni sistematika tal-2025 ta’ prodotti b’ konċentrazzjoni għolja ta’ THC sab assoċjazzjonijiet kostanti sfavorevoli ma’ riżultati ta’ psikożi/skiżofrenija u vizzju tal-użu tal-cannabis, b’sinjali ta’ tħassib għall-ansjetà u d-depressjoni [15].

Għal Malta: Id-delta-9 THC għandu rilevanza terapewtika leġittima imma fih rekwiżiti ċari ta’ intossikazzjoni, psjikiċi, u sikurezza relatata mad-dożaġġ. Il-formula tagħna fiha biss 90 mg totali—3 mg/mL—dramatikament inqas mill-600-900 mg/jum ta’ RSO tradizzjonali. Dan jirrifletti kuxjenza moderna tas-sikurezza filwaqt li tpreserva l-potenzjal terapewtiku.

CBN (Kanabinol) — 750mg f’Żejt Sottolingwali

Profil tal-Evidenza: Evidenza tal-bniedem dgħajfa; il-marketing ċar li mexxa ‘l quddiem mil-data [12][16][17].

Talbiet tan-Nemus: CBN huwa mmarketjat wiesa’ għan-nemus, iżda reviżjoni tal-2021 skrinjat 99 sommarju ta’ studji tal-bniedem u ma sab l-ebda provi kliniċi jużaw questionnaires validati tan-nemus jew polysomnografija li jistgħu jiċċertifikaw talbiet qawwija għax-xewmija [16].

Letteratura Aktar Wiesgħa tan-Nemus: Reviżjoni tal-2024 waslet għall-konklużjoni li r-riċerka tan-nemus tal-kannabinoids għadha ma tikkorrispondix mal-iskala ta’ użu reali, b’bżonn ta’ provi aħjar ddiżinjati, b’qawwa adegwata [17].

Għal Malta: Il-CBN huwa wieħed mill-eżempji l-iktar ċari fejn ir-reputazzjoni kulturali taqbeż l-evidenza klinika. Inkludieħ b’750 mg (25 mg/mL) għaliex il-klijenti tagħna jirrapportaw benefiċċji tan-nemus, u aħna trasparenti dwar il-vojt tal-evidenza u l-fatt li l-prodott mhux mahsub biex jiddijanjosika, jikkura, jikkura, jew jipprevjeni l-marda.

CBC (Cannabichromene) — 750mg f’Żejt Sottolingwali

Profil tal-Evidenza: Emerġenti, interessanti, maqbula bla waqfan preklinika jew bbażata fuq reviżjoni [18][19].

Farmakoloġija: Reviżjoni tal-2024 targumenta li l-CBC għandu dinamika farmaċewtika distinta, farmaċokinetika, u ħġieġ ta’ riċetturi, jenfasizza oqsma kontra n-nokkev, antibatterjali, u kontra l-epilessija bħala mira interessanti ta’ riċerka [18].

Twissija ta’ Sikurezza: Ir-reviżjoni tal-CBC tal-2024 tiddikjara espliċitament li prodotti CBC over-the-counter qed jinbiegħu minkejja ftit evidenza li tistabbilixxi effikaċja klinika jew sikurezza [18].

Għal Malta: Il-CBC jappartjeni għall-kategorija ta’ kannabinoids minor xjentifikament kredibbli li jistħoqq aktar riċerka, mhux attivi kliniċi diġà validati. Aħna trasparenti dwar l-istatus investigazzjonali tiegħu.

Profili Terpene: Il-Ħdax-il Kompund Aromatiku

It-terpenes jeħtieġu interpretazzjoni anqas stretta mill-kannabinoids. Ħafna letteratura tiġi minn komposti isolati, żjut essenzjali, pjanti mhux tal-cannabis, jew mudelli preklinici. Reviżjoni tal-2024 tal-effett entourage tagħmel dan ċar: il-bioattività tal-terpene hija plausibbli iżda l-prova robusta ta’ effetti entourage klinikament sinifikanti fl-bniedem għadha limitata [20][29].

Limonene — Ħelu taċ-Ċitru

Evidenza: Largament reviżjoni u preklinika [20]-[22]. Reviżjoni tal-2021 tiddeskrivi possibilitajiet antioksidanti, anti-infjammatorji, kardjoproteġġenti, gastoproteġġenti, u immunomodulatorji, imma ħafna talbiet ġejjin minn letteratura mhux tal-bniedem [21].

Nota ta’ Sikurezza: Il-prodotti ta’ ossidazzjoni tal-limonene, speċjalment l-idroperossidi, huma allergeni ta’ kuntatt klinikament relevanti importanti fit-testijiet tal-patch [22].

Konnessjoni ma’ Malta: Jekk int f’Malta, int mdawwar bil-ċitru—lumi, larinġ, l-arja mediterranja. Taf ir-risq u uplifting tal-limonene mill-ħajja kuljum. Inkludieh għal dik il-familiarità sensorja u proprjetajiet plausibbli ta’ appoġġ tal-mood.

Mirċen

Evidenza: Iħawwel aktar preklinika, evidenza tal-bniedem pjuttost limitata [20][23]. Reviżjoni tal-2021 tiddeskrivi proprjetajiet ansjioliticiċi, antioksidanti, anti-infjammatorji, u analġeżiċi imma tiddikjara espliċitament li l-istudji tal-bniedem jonqsu [23].

Konnessjoni ma’ Malta: Il-mirċen jinsab fil-mango, is-saħn, u l-lemongrass—flavors familjari għal palati Maltin. It-talba li l-mirċen jikkawża “couch-lock” hi aktar qawwa mill-evidenza attwali tal-bniedem.

Kariofillene (β-kariofillene) — Filfil/Bżar

Evidenza: Fost it-terpenes l-iktar interessanti meġġaniċament għaliex jaġixxi bħala agonist selettiv tar-riċettur CB2 [24]. Reviżjoni tal-2021 tiddiskudi azzjonijiet kontra l-infjammazzjoni, immunomodulatorji, antioksidanti, newroproteġġenti, gastoproteġġenti, imma l-konferma klinika tal-bniedem għadha limitata [24].

Konnessjoni ma’ Malta: Il-bżar iswed huwa universali, inkluż fil-kċejjen Maltin. L-agoniżmu CB2 tal-kariofillene jagħmlu partikolarment rilevanti meta niddiskutu farmaċoloġija tal-cannabis minflok biss riħ.

Pinene — Ffrisk mill-Foresti

Evidenza: Letteratura premittenti preklinika, dewmien kliniku dgħajjef [20][25]. Reviżjoni tal-2021 sab sinjali antioksidanti, kontra l-infjammazzjoni, u newroproteġġenti li jiġġustifikaw studji futuri, imma enfasizzat nuqqas ta’ provi kliniċi ddiżinjati sew [25].

Konnessjoni ma’ Malta: Il-foresti tal-pine ta’ Malta f’postijiet bħal Buskett Gardens jagħtuk ir-riħ frisk tal-pinene. Filwaqt li t-talbiet dwar it-tejbin tal-memorja għadhom esploratorji, il-konnessjoni sensorja hija reali għall-ħbieb tan-natura Maltin.

Linalool — Fjur, Lavender

Evidenza: Interess sostanzjali prekliniku, dewmien kliniku dirett limitat [20][22][25][26]. Reviżjoni tal-2021 tas-saħħa tal-moħħ sab sinjal biżżejjed biex jiġġustifika investigazzjoni kontinwa f’kuntesti newroloġiċi u psikjatrik [25].

Nota ta’ Sikurezza: L-idroperossidi tal-linalool ossidati huma allergeni rikonoxxuti [22].

Konnessjoni ma’ Malta: Lavender tikber sabiħa fil-klima mediterranja ta’ Malta. Ir-riħ kalma tal-linalool huwa familjari kemm jekk int f’ġnien Malti jew tuża żjut essenzjali d-dar.

Humulene — Teral tal-Art, Injam

Evidenza: Interessanti interpretazzjonalment imma bikrija [20][27]. Reviżjoni tal-2024 ta’ skoping ta’ 340 artiklu sab evidenza wiesgħa preklinika għal effetti kontra l-infjammazzjoni, b’xi xogħol fuq l-irgus jissuġġerixxi proprjetajiet kannabimimetiċi [27].

Konnessjoni ma’ Malta: Ir-riħ tal-art jgħaqqad max-xogħol agrikolu ta’ Malta—għadajjar ta’ żebbuġ, vigneti, u ġnien tal-ħwawar.

Terpinolene — Aroma tal-Pine, tal-Frott, Sfaċċat

Evidenza: Wieħed mit-terpenes l-inqas karatterizzati klinikament [20][28]. Reviżjoni tal-2021 skrinjat 2,429 rekord u waslet għall-konklużjoni li l-bażi tal-evidenza hija ddominata minn studji in silico, in vitro, u fuq l-annimali [28].

Konnessjoni ma’ Malta: Il-profil kompless tar-riħ tal-terpinolene żżid brightness għall-esperjenza sensorja tal-prodott tagħna—xi ħaġa li konsumaturi Maltin li japprezzaw l-artiġjanat ta’ kwalità se ssib.

Il-Formuli RSO Tagħna: Trasparenza Sħiħa

Żejt Sottolingwali RSO — $129.99

Kannabinoid	Ammont (mg)	% tat-Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590mg	100%

Speċifikazzjonijiet Addizzjonali:

• Terpeni Ħajjin: 5% (limonene, mirċen, kariofillene, pinene, linalool, humulene, terpinolene)
• Format: 30mL flixkun (1 fl oz)
• Kannabinoids attivi kull mL: 553mg
• Trasportatur: Żejt MCT organiku
• Dożaġġ: Siringa gradwata b’inkrementi ta’ 0.1mL
• Bidu: 15-45 minuta (sottolingwali)
• Punt massimu: 1-2 siegħa
• Tul: 4-6 sigħat
• Biodisponibilità: 13-19%
• Dożi approssimattivi kull flixkun: 40-60 (tiddependi mid-daqs tas-servuta)

Għal Malta: Din hija l-formula RSO multi-kannabinoid l-iktar komprensiva disponibbli. F’553mg/mL, hija esċezzjonalment konċentrata. Is-siringa gradwata tippermetti dożaġġ preċiż—kritiku għal pazjenti Maltin li għandhom bżonn titratura bir-reqqa. Il-bażi ta’ żejt MCT organiku tipprovdi assorbiment nadif u konsistenti.

Kartuċċa RSO Vape — $49.99

Kannabinoid	Perċentwal
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Speċifikazzjonijiet Addizzjonali:

• Terpeni Ħajjin: 5%+
• Format: Kartuċċa ta’ 1-gramm
• Kannabinoids totali: 900mg+
• Xaft: Batterija universali 510-thread
• Bidu: 1-2 minuta (kunsinna l-iktar malajr)
• Punt massimu: 10-15 minuta
• Tul: 2-4 sigħat
• Biodisponibilità: 10-35%
• Dekarbossalazzjoni awtomatika: Tikkonverti THCa f’delta-9 THC f’400-450°F immedjatament

Għal Malta: Il-format vape huwa ideali għal uġigġ breakthrough, ansjetà akuta, jew nauseu—sitwazzjonijiet fejn pazjenti Maltin jeħtieġu sollieħ immedjat. Il-kompatibilità 510-thread ifisser li taħdem ma’ batteriji standard disponibbli f’ħwienet tal-vape madwar Malta.

Kif il-Formula Tagħna Tiddiverġi minn RSO Tradizzjonali

Dimensjoni	RSO Tradizzjonali	RSO Formulat minn OilWell
Materjal tas-sors	Tant wieħed ta’ razza high-THC indika, mhux kontrollat	Kombinazzjoni multi-kannabinoid minn sorsi multipli
Metodu ta’ estrazzjoni	Naphtha jew alkoħol isopropyl	Metodi moderni ta’ etanoll ta’ grad tal-ikel jew CO₂
Profil kannabinoid	Domminanti minn THC, mhux kontrollat	Seba’ kannabinoids definiti f’relazzjonijiet speċifiċi
Kontenut terpene	Distrutt mis-sħana	Terpeni ħajjin f’5% b’profil definit
Standardizzazzjoni	Xejn—kull batch differenti	Ttestjat fil-lab b’għanijiet mg/mL (553mg/mL)
Ttestjar fil-lab	Mhux esegwit	Ttestjar full panel (potenza, terpeni, pestiċidi, metalli tqal, solventi residwi, mikrobijali)
Solventi residwi	Riskju signifikanti ma’ naphtha	Kontrollat u ttestjat
Preċiżjoni tad-dożaġġ	Bbażata fuq siringa approssimattiva	Mkejjel kull 0.1mL b’kontenut magħruf
Formats tal-prodott	Żejt wieħed biss	Żejt sottolingwali + kartuċċa vape
Preżervazzjoni tal-THCa	Le—dekarbossilata kompletament	Iva—1,500mg bħala ingredjent separat
Domminanza delta-9 THC	60-90% tal-kannabinoids	Biss 90 mg totali (0.5% tal-formula)
Approċċ tal-evidenza	Xhud anekdotiku, testimonjanza personali	Bbażat fuq riċerka, ppeżat skond l-evidenza

Għaliex Dan Huwa Importanti f’Malta: RSO tradizzjonali kien krudu, varjabbli, u potenzjalment mhux sikur. Il-formula tagħna tirrapreżenta l-evoluzzjoni li jistħoqq il-konsumaturi Maltin discernenti—preċiżjoni, sikurezza, u trasparenza.

Il-Vantaġġ Uniku ta’ Malta: Potenza Kontrollata mill-Pazjent

Il-formula tagħna tagħti lill-konsumaturi Maltin tliet għażliet ta’ użu distinti:

Għażla 1 — Mhux Ippreċessat (Mhux Psikotropiku): Uża ż-żejt kif inhu. L-1,500mg THAa kollha jibqgħu aċidużi, ma jipproduċu l-ebda effett psikotropiku. Ideal għal professjonisti Maltin li għandhom bżonn sollieħ tul il-jum mingħajr ħsara—tabbijiet, avukati, għalliema, sidien tan-negozju li għandhom jibqgħu ċatti.

Għażla 2 — Attivat Sħiħ (Dekarbossalazzjoni D-dar): Sħun iż-żejt f’260°F (125°C) għal 45-60 minuta. Dan jikkonverti 1,500mg THCa f’approssimattivament 1,315mg delta-9 THC. Magħquda mal-90mg delta-9 eżistenti, tikseb ~1,405mg delta-9 THC totali—potenza komparabbli ma’ RSO illegali tradizzjonali, kompletament skont id-diskrezzjoni tiegħek wara xiri legali.

Għażla 3 — Attivazzjoni Parzjali: Ittrasferixxi porzjon kontrollat (pereżempju 5mL) f’kontenitur separat adatt għall-forn, dekarbossalaxxa biss dak il-porzjon, u żomm l-bqija mhux ipproċessat. Dan jippermettilek iżżomm kemm provvista ta’ jum mhux psikotropika u provvista attivata tal-lejl mill-istess flixkun.

Kimika tal-Konverżjoni: THCa (MW 358.47 g/mol) tikkonverti f’relazzjoni ta’ 1mg THCa = 0.877mg delta-9 THC, tirrifletti t-telf ta’ CO₂ tul id-dekarbossalazzjoni.

Għal Malta: Din il-potenza kontrollata mill-pazjent hija rivoluzzjonarja. L-liġijiet tal-cannabis ta’ Malta jistgħu jkunu restrittivi (aċċess mediku biss, kundizzjonijiet kwalifikanti limitati). Il-prodott tagħna huwa konformi mal-Farm Bill fl-ixiri—inqas minn 0.3% delta-9 THC—li jagħmlu legalment aċċessibbli. L-għażla li tattiva hija tiegħek, magħmula private, wara akkwiżizzjoni legali. Dan jirrispetta kemm il-liġi Maltija kif ukoll l-awtonomija tal-pazjent.

Qafas Legali: Kif ir-Residenti ta’ Malta Jistgħu Jiksbu l-Prodotti Tagħna

Konformità mal-Farm Bill u Tbaħħir Internazzjonali

Il-Farm Bill tal-2018 legalizzajha prodotti derivati mill-ħemp li fihom inqas minn 0.3% delta-9 THC skond il-piż niexef fil-livell federali fl-Istati Uniti. Dan huwa l-fondament tad-disinn tal-prodott RSO tagħna.

Iż-żejt sottolingwali tagħna fih biss 90mg delta-9 THC fl-30mL flixkun totali—3mg/mL—’l isfel mill-limitu ta’ 0.3%. Il-kannabinoids kollha huma derivati mill-ħemp. Il-prodott huwa legali skond il-liġi federali tal-Istati Uniti u fl-istatistika l-kbira tal-istati.

Tbaħħir Internazzjonali lejn Malta: Aħna nibgħatu madwar id-dinja, inkluż lejn Malta. Peress li l-prodott tagħna fih inqas minn 0.3% delta-9 THC fil-punt tal-bejgħ, jissodisfa d-definizzjoni ta’ prodott derivat mill-ħemp u huwa tbaħħar għal ġurisdizzjonijiet b’liġijiet tal-ħemp kompatibbli.

Avviż Legali Importanti: Il-THCa tikkonverti għal delta-9 THC meta tisħun. Il-klijenti Maltin huma responsabbli biex jifhmu u jikkonformaw mal-liġijiet lokali dwar il-prodotti tal-kannabinoids. Aħna nibgħatu b’dokumentazzjoni sħiħa, Ċertifikati ta’ Analiżi (COA), u rċevuti. Il-klijenti internazzjonali jaċċettaw ir-responsabbiltà kollha tal- dogana u legali.

Speċifikament għal Malta: Malta legalizzat il-cannabis medika fl-2018 u l-cannabis rikreattiva fl-2021 (l-ewwel pajjiż tal-UE). Madankollu, l-aċċess għadu limitat, il-prodotti huma għaljin, u ħafna pazjenti jippreferu jfasslu minn fornituri internazzjonali reputabbli. Il-prodotti konformi mal-Farm Bill tagħna jistgħu jidħlu legalment f’Malta bħala suppliments derivati mill-ħemp, sakemm jissodisfaw ir-rekwiżiti tal-importazzjoni lokali. Inkludew COAs kompluti biex jiffaċilitaw il-clearance tal- dogana.

Dikjarazzjoni ta’ Responsabbiltà tal-Klijent

Rekwiżit ta’ Età: 21+ għal prodotti RSO kollha

Disclaimer tal-FDA: Dawn il-prodotti ma ġewx evalwati mill-Food and Drug Administration. Mhumiex mahsuba biex jiddijanjosaw, jikkuraw, jikkuraw, jew jipprevjenu kwalunkwe marda. L-riżultati individwali jistgħu jvarjaw. Konsulta fornitur tal-kura tas-saħħa qabel l-użu, speċjalment jekk għandek kundizzjoni mediċi, qed tieħu mediċini, int tqila jew tredda’, jew għandek tħassib dwar is-saħħa.

Twissijiet ta’ Sikurezza: Tista’ tikkawża għajjien jew ħsara. Tpoġġix vetturi jew magħmula taħt l-effett ta’ kannabinoids psikotropiċi. Żomm bogħod minn tifal. Aħżen f’post kesħ, niexef ‘il bogħod mis-sħana u d-dawl biex tevita d-dekarbossalazzjoni tal-THCa jekk trid tipproteġi l-forma mhux ipproċessata.

Responsabbiltà Legal: L-xerrej jaċċetta r-responsabbiltà kollha għall-konformità mal-liġi lokali Maltija. OilWell ma jassumix responsabbiltà legali għall-użu jew id-deċiżjonijiet ta’ dekarbossalazzjoni tal-klijent. Annullat fejn huwa proibit mil-liġi.

Kunsinna u Aċċessibbiltà għal Malta

Tbaħħir Internazzjonali lejn Malta

Aħna nibgħatu lejn Malta permezz ta’ USPS Priority Mail International (6-10 jiem tan-negozju) jew FedEx International (3-5 jiem tan-negozju). Il-pakketti kollha jinkludu:

• Ċertifikat ta’ Analiżi (COA) komplut għall- dogana
• Deskrizzjoni dettaljata tal-prodott u rċevut
• Ippakkjar diskret mingħajr branding tal-cannabis viżibbli
• Numru ta’ traċċar pprovdut
• Ippakkjar stabbli fit-temperatura għall-klima mediterranja

Spiża tat-Tbaħħir: Tbaħħir internazzjonali flat rate japplika. Ikkuntattjana f’[email protected] jew (832) 416-2816 għar-rati attwali lejn Malta.

Kunsiderazzjonijiet tal-Customs: L-awtoritajiet tal- dogana ta’ Malta jistgħu jiċċekkjaw il-pakketti. Id-dokumentazzjoni kompluta tagħna tiżgura trasparenza. Ma nistgħu niżgurawx iż-żminijiet tal-kunsinna minħabba l-ipproċessar tal- dogana, iżda bdejna b’suċċess lejn Malta u pajjiżi oħra tal-UE.

Ħlas: Il-klijenti internazzjonali jistgħu jħallsu permezz ta’ karta tal-kreditu jew kriptovaluta. Il-transazzjonijiet kollha jiġu proċessati b’sikurezza.

Għaliex L-Aċċess Internazzjonali Huwa Importanti għal Malta

F’Malta, il-cannabis medika hija legali imma l-aċċess jista’ jkun sfidanti. In-numru limitat ta’ spiżeriji awtorizzati li jorbtu, ir-rekwiżit għal riċetti speċifiċi, u l-prezz għoli jolqtu ostakli. Il-programm tat-tbaħħir internazzjonali tagħna jfisser li pazjenti Maltin li ma jistgħux jiksbu jew jaffordjaw prodotti medici ta’ cannabis lokali għandhom alternattiva legali, trasparenti, ta’ kwalità għolja.

Rick Simpson ma setax jibgħat l-żejt tiegħu mknien—kien Skeda I, illegali biex jiġi prodott, possedut, jew trasportat. Pazjent tal-kanċer f’Mdina, sofferent tal-uġigġ kroniku f’St. Julian’s, jew veterinarju f’Paola issa jistgħu potenzjalment jiksbu l-istess formula multi-kannabinoid ta’ potenza klinika li r-residenti ta’ Houston jirċievi permezz ta’ kunsinna fl-istess jum. Bnejna prodott li jista’ jgħaddi mill-fruntieri legalment, jikkompleta biċċa mill-viżjoni ta’ Rick Simpson li l-projbizzjoni għamlet impossibbli tul ħajtu.

Kuntest ta’ Użu Speċifiku għal Kundizzjoni għal Malta

Disclaimer Kritiku: Dawn il-kuntesti ta’ użu huma infurmati mir-riċerka tal-kannabinoids imsemmija fis-sezzjoni tal-Għarfien Ġenerali tagħna. M’HUMIEX mediċini mediċi, M’HUMIEX protokolli ta’ kura approvati mill-FDA, u M’HUMIEX sostitut għal kura mediċika professjonali. Dawn il-prodotti mhumiex mahsuba biex jiddijanjosaw, jikkuraw, jikkuraw, jew jipprevjenu kwalunkwe marda. Dejjem ikkonsulta fornitur ta’ kura tas-saħħa kwalifikat qabel l-użu ta’ prodotti kannabinoid. Tpoġġix vetturi jew magħmula taħt l-effett.

Għal Malta: Ninkoraġġukom tiddiskutu kwalunkwe użu ta’ kannabinoid mat-tabib Malti tiegħek, kemm jekk tirċievi kura f’Mater Dei Hospital, klinika privat f’Sliema, jew permezz tas-servizz tas-saħħa nazzjonali ta’ Malta. Prattikanti tal-mediċina integrattiva f’Malta jistgħu jkunu partikolarment miftuħin għal dawn id-diskussjonijiet.

Nauseu Relatata ma’ Kimoterapija u Appoġġ għall-Aptit

• Pre-kimoterapija: 0.5-1.0mL sottolingwali madwar siegħa qabel it-trattament
• Nauseu akuta breakthrough: 2-3 puff tal-vape għal sollieħ immedjat (bidu 1-2 minuta)
• Post-kimoterapija: 0.5mL sottolingwali kull 6 sigħat kif meħtieġ
• Appoġġ tan-nemus tul it-trattament: 1.0-2.0mL sottolingwali qabel l-irqad (tipprovdilha 25-50mg CBN)
• Evidenza: Anti-emetiku tal-delta-8 [9], nauseu/qerda tal-delta-9 [1][13], buffering ansjiolittiku tal-CBD [3]

Għal Malta: Jekk qed tgħaddi kimoterapija f’Sir Paul Boffa Hospital jew klinika onkoloġika privat, it-terapija tal-kannabinoid tista’ tgħin timmaniġġja l-effetti sekondarji. Il-format vape tagħna huwa partikolarment valutabbli għal nauseu akuta li tibqa’ f’daqqa.

Uġigġ Kroniku (Fibromialġja, Artrite, Newropatija)

• Jum: 0.3-0.5mL mhux ipproċessat sottolingwali—kontra l-infjammazzjoni mingħajr ħsara psikotropika
• Lejl: 0.5-1.0mL sottolingwali dekarbossalat—jikkombina sollieħ mill-uġigġ ma’ appoġġ tan-nemus tal-CBN
• Uġigġ breakthrough: Vape kif meħtieġ għal bidu malajr
• Evidenza: Uġigġ tal-CBD [4], uġigġ tal-delta-9 THC [13], agoniżmu CB2 tal-beta-kariofillene [24], inibizzjoni COX-2 tal-THCa [12]

Għal Malta: L-uġigġ kroniku jaffettwa ħafna residenti Maltin, speċjalment dawk f’xogħolijiet fiżikament intensivi jew jiffaċċjaw kundizzjonijiet relatati mal-età. L-għażla tagħna ta’ jum mhux ipproċessat tippermettilek taħdem mingħajr ħsara filwaqt tirċievi appoġġ kontra l-infjammazzjoni.

Appoġġ tan-Nemus

• Qabel l-irqad: 1.0-2.0mL sottolingwali
• F’2.0mL: Tipprovdilha 50mg CBN—il-livell ta’ dożaġġ investigat fil-letteratura tan-nemus tal-2024
• F’1.0mL: Tipprovdilha 25mg CBN—’l fuq mill-limitu ta’ 20mg assoċjat ma’ tnaqqis fid-disturb tan-nemus
• Evidenza: Nemus tal-CBN [16][17], letteratura ta’ reviżjoni tal-cannabis u n-nemus

Għal Malta: It-trastorni tan-nemus huma komuni f’żoni urbani mgħaġġla ta’ Malta. Il-kontenut CBN tagħna huwa sostanzjali, għalkemm naċċettaw li l-bażi tal-evidenza għadha limitata meta mqabbla mat-talbiet tal-marketing.

Ansjetà u Stress

• Sollieħ funzjonali tul il-jum: 0.3mL mhux ipproċessat sottolingwali—CBD u CBG jindirizzaw il-pathways tal-ansjetà mingħajr ħsara
• Lejl: 1.0mL sottolingwali—profil sħiħ inkluż CBN għall-istruttura tan-nemus
• Evidenza: Ansjetà tal-CBD [3], farmakoloġija tal-CBG [7][8], evidenza entourage tal-limonene [20]

Għal Malta: Kemm jekk qed tiffaċċja stress tax-xogħol fl-ambjent tan-negozju competitiv ta’ Malta jew ansjetà minn tħassib tas-saħħa, l-għażla tagħna ta’ jum mhux ipproċessat tipprovdi appoġġ mingħajr effetti psikotropiċi.

Prinċipju Ġenerali tat-Titraġġ għal Malta

Ibda baxx, mur bil-mod. Ibda b’0.25-0.5mL sottolingwali u evalwa l-effetti fuq 2-3 sigħat qabel ma żżid. Ir-risposti individwali jvarjaw skond il-piż tal-ġisem, il-metaboliżmu, it-tolleranza, il-mediċini konkorrenti, u fatturi oħra.

Kunsiderazzjonijiet Speċifiċi għal Malta: Dieti mediterranji, mediċini lokali, u ġenetika individwali kollha jaffettwaw il-metaboliżmu tal-kannabinoids. Il-pazjenti Maltin għandu jkunu speċjalment konservattivi jekk ġodda għall-kannabinoids.

Paragun Kompetittiv: Għaliex OilWell għal Malta?

OilWell RSO vs. Programm tal-Cannabis Medika ta’ Malta

Dimensjoni	Cannabis Medika ta’ Malta	OilWell RSO
Għażliet kannabinoid	Limitati għal prodotti approvati	7 kannabinoids f’relazzjonijiet preċiżi
Rekwiżiti ta’ aċċess	Riċetta speċifika tal-tabib, kundizzjonijiet kwalifikanti	Età 21+, l-ebda karta medika meħtieġa
Għażliet THC	Dożi restritti	Kontrollata mill-pazjent (minn mhux ipproċessat sa 1,405mg attivat)
Kontenut terpene	Varjabbli, ħafna drabi minimu	5% terpeni ħajjin b’profil definit
Ttestjar fil-lab	Meħtieġ imma r-riżultati jistgħu ma jkunux pubbliċi	COAs sħiħ disponibbli pubblikament fuq talba
Prezz	Għoli (suq regolat)	$129.99 għal 30mL (16,590mg kannabinoids totali)
Kunsinna	Meħtieġ pickup mill-ispiżerija	Tbaħħir dirett lejn Malta
Aċċess internazzjonali	Mhux disponibbli	Tbaħħir dinjata disponibbli

Għal Malta: Il-programm tal-cannabis medika ta’ Malta, għalkemm progressiv fl-UE, għadu restrittiv. Il-prodott tagħna joffri divertità tal-kannabinoids, kontroll mill-pazjent, u aċċess dirett li l-programm ta’ Malta ma jaqblux.

OilWell RSO vs. Prodotti Ewropej biss b’CBD

Dimensjoni	Żejt CBD Tipiku tal-UE	OilWell RSO
Kannabinoids totali	500-2,000mg	16,590mg
Kontenut CBD	500-2,000mg	4,500mg
Kontenut CBG	0-50mg	3,000mg
Kontenut CBN	0-20mg	750mg
Delta-8 THC	0mg	6,000mg
THCa	Minimu	1,500mg
Delta-9 THC	<0.2% (limitu tal-UE)	90mg (<0.3% f’bejgħ, konvertibbli għal 1,405mg)
Għażla psikotropika	Le	Iva—kontrollata mill-pazjent
Terpenes	Ħafna drabi minimu	5% terpeni ħajjin
Prezz	€50-120	€120 ekwivalent għal divertità kannabinoid superjuri

Għal Malta: L-żjut CBD Ewropej ħafna drabi huma prodotti kannabinoid wieħed b’potenzjal terapewtiku limitat. Il-formula tagħna tippprovdi seba’ kannabinoids f’livelli terapewtici, flimkien ma’ terpenes, għal appoġġ komprensiv.

Filosofija Open-Source: Rigalna lill-Malta

Għaliex Nippubblikaw Kollox

Rick Simpson ta l-żejt tiegħu ‘il bogħod b’xejn u għallem lin-nies kif jagħmluh. Qatt ma patentja l-metodu tiegħu. Dak l-etos huwa fundamentali għall-moviment RSO.

Aħna addattajna dik il-filosofija għas-suq modern tal-kannabinoids: nbigħ prodott manifatturat professjonament, ttestjat fil-lab, standardizzat għal dawk li jriduh, u nippubblikaw ir-riċetta kompluta għal dawk li jridu jagħmluh waħedhom.

Ir-Riċetta Sħiħa ta’ RSO ta’ Malta

Jekk int f’Malta u ma tistax taffordja l-prodott tagħna ta’ $129.99—jew sempliċement trid tagħmel tiegħek stess—għandek kollox li għandek bżonn f’dan id-dokument. Sors distillati u isolati ta’ kannabinoids derivati mill-ħemp minn fornituri Ewropej reputabbli (ħarġilhom huma jipprovdu COA), immixa skond is-speċifikazzjonijiet eżatti tagħna, u oħloq il-verżjoni tiegħek stess.

Nippreferu li jkollok aċċess sikur milli l-ebda aċċess. Dak huwa l-impenn li għamel Colin fl-2019 fuq ABC13, u l-impenn li nlestu lejn Malta llum.

Ħsibijiet Finali: Messaġġ għal Malta

Malta, narakom. Narakom il-kostijiet sbieħ, in-nies reżiljenti, il-kurjożità dejjem tikber dwar il-mediċina tal-kannabinoids. Narakom il-pazjenti tal-kanċer f’Sir Anthony Mamo Oncology Centre jfittxu għażliet. Narakom il-veterani f’Valletta jissoġraw bil-PTSD. Narakom is-sofferenti tal-uġigġ kroniku f’Gozo li ppruvaw kollox.

Aħna konna fejn int. Gabrni d-desperazzjoni, t-trattament infurmat, it-tama li xi ħaġa aħjar tista’ teżisti. L-istorja ta’ Bentley għallimna li l-kannabinoids jistgħu jagħmlu affarijiet li l-prodotti farmaċewtiċi ma jistgħux. Il-battalja personali ta’ Colin mat-tluq mill-benzo għallimna li dawn il-komposti tal-pjanta jistgħu litteralment isalvaw il-ħajjiet.

Dak li qed noffrulhom Malta mhuwiex biss prodott. Huwa filosofija:

• Aċċessibbiltà minn gatekeeping — L-ebda karta medika meħtieġa, tbaħħir internazzjonali disponibbli
• Potenza kontrollata mill-pazjent — Int tiddeċiedi jekk tużax mhux ipproċessat jew attivat
• Formuli open-source — Jekk ma tistax taffordja, agħmelha waħdek
• Onestà infurmati mill-evidenza — Ngħidulek dak li nafu, dak li ma nafx, u dak li għadna nitgħallmu

Minn Houston sa Malta, mill-mirakolu ta’ Bentley sal-vjaġġ tiegħek, aħna hawn biex nipprovdu l-aħjar verżjoni possibbli ta’ edukazzjoni RSO sabiex tagħtiha xorti ġusta u tiddeċiedi jekk hijiex tajba jew ħażina għalik.

Ikkuntattjana:
Telefon: (832) 416-2816
Email: [email protected]
Websajt: https://oilwellcbd.com/
Instagram: @oilwellcbd

Nibgħatu lejn Malta. Nappoġġaw Malta. Nmerħba lil Malta fil-komunità ta’ OilWell.

Disclaimer: Dan il-kontenut huwa għal skopijiet edukattivi u ta’ informazzjoni biss. Dawn il-prodotti ma ġewx evalwati mill-Food and Drug Administration jew kwalunkwe awtorità regolatorja Maltija. Mhumiex mahsuba biex jiddijanjosaw, jikkuraw, jikkuraw, jew jipprevjenu kwalunkwe marda. Dejjem ikkonsulta fornitur ta’ kura tas-saħħa kwalifikat qabel l-użo ta’ prodotti kannabinoid. Tpoġġix vetturi jew magħmula taħt l-effett. Żomm bogħod minn tifal. L-xerrej jaċċetta r-responsabbiltà kollha għall-konformità mal-liġi Maltija. OilWell ma jassumix responsabbiltà legali għall-użu jew id-deċiżjonijiet ta’ dekarbossalazzjoni tal-klijent. L-riżultati individwali jistgħu jvarjaw. Din l-informazzjoni ma tikkostitwixxix parir mediċu għar-residenti ta’ Malta.

ENGLISH

Rick Simpson Oil (RSO) in Malta: The Complete Guide by OilWell Cannabis

Why We’re Reaching Out to Malta

From our home in Houston, Texas, we’ve been watching how the conversation around cannabis medicine has evolved across the globe. Malta—this remarkable Mediterranean island with its rich history, tight-knit communities, and forward-thinking approach to healthcare policy—has emerged as a place where people are asking the right questions about cannabinoid therapy. We know that in Malta, as in Houston, families are navigating cancer treatment decisions, veterans are struggling with PTSD, chronic pain patients are cycling through ineffective prescriptions, and pet owners are facing that gut-wrenching moment when conventional medicine says there’s nothing more to do.

We’re writing this guide because Malta deserves the same honest, evidence-based RSO education that has made OilWell Cannabis a trusted name in America’s fourth-largest city. Whether you’re reading this from Valletta’s historic streets, Sliema’s bustling waterfront, or the quiet countryside of Gozo, you deserve to understand what Rick Simpson Oil actually is, what science supports, what it can and cannot do, and how our modern, lab-tested, multi-cannabinoid formulas solve the problems that traditional RSO never could.

This isn’t marketing copy written by an agency. This is us—OilWell Cannabis—speaking directly to you in Malta, sharing everything we’ve learned from a decade of formulation work, seven ABC13 news features, and the real-world experience of helping thousands of patients. Every number we share, every study we cite, every formula we publish is verifiable. We’re not here to sell you hope. We’re here to give you the information you need to decide what’s right for you and your loved ones.

Understanding Rick Simpson Oil: The Real Story

Who Was Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical researcher—he was a power engineer and maintenance worker, a blue-collar tradesman who found his way to cannabis medicine through personal suffering. In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine failed to resolve. The medications prescribed either didn’t help or made things worse. When he asked his physician about cannabis, the request was refused.

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC reportedly slowed tumor growth in mice. That study—originally designed to demonstrate harm—became Simpson’s foundational reference, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm, diagnosed as basal cell carcinoma, disappeared after four days of applying concentrated cannabis oil directly to the lesions. No independent medical verification, biopsy confirmation, or clinical follow-up was ever published. This personal experience—untested as medical evidence—became the origin story of Rick Simpson Oil and launched a global movement.

Why This Matters for Malta: Many in Malta have faced similar moments—when the medical system offers no more options, when treatments fail, when you’re told to prepare for the worst. The desperation that drove Simpson is universal. It drives Maltese cancer patients to search online at 2 AM, drives Gozitan chronic pain sufferers to ask their doctors about alternatives, drives Valletta veterans to seek relief from PTSD when pharmaceuticals have failed them. Understanding Simpson’s story means understanding the desperation that makes RSO relevant—but it also means understanding the critical difference between personal testimony and medical proof.

The 60-Gram Protocol: What Simpson Actually Recommended

Simpson’s core treatment recommendation was a 90-day protocol designed to deliver 60 grams of concentrated cannabis oil. Here’s exactly what he prescribed:

Week 1: Start with a dose the size of half a grain of rice—about 10-15 mg of oil—three times daily. Total daily intake: 30-45 mg.

Weeks 2-5: Double the dose every four days. By week five, reach 1 gram (1,000 mg) per day, divided into three doses of roughly 333 mg each.

Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed.

Simpson recommended oral administration (sublingual or swallowed) as primary, topical application for skin conditions, and acknowledged inhalation for immediate symptom relief but not as the main treatment.

Critical Context for Malta: At peak dosing, traditional RSO delivered approximately 600-900 mg of delta-9 THC per day. That dose far exceeds anything studied in controlled clinical settings. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 mg per day. Consuming 600-900 mg daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. For Maltese patients already dealing with complex medical conditions, these risks cannot be ignored.

What Traditional RSO Actually Was

Traditional Rick Simpson Oil was:

• Source material: Single high-THC indica strain, unstandardized
• Extraction solvent: Naphtha (petroleum-based) or 99% isopropyl alcohol—neither food-grade
• Process: Bucket, solvent, agitation, filtering, rice cooker evaporation, syringe storage
• Appearance: Nearly black, thick, tar-like oil with solvent-residual odor
• Cannabinoid profile: 60-90% delta-9 THC, fully decarboxylated, no ratio control, never lab-verified
• Terpenes: Effectively destroyed by solvent and heat
• Standardization: None—every batch different
• Testing: No COAs, no contaminant screening
• Safety: Significant residual solvent risk, especially from naphtha which may contain benzene, toluene, and other carcinogens

The Malta Connection: If you’re in Malta and you’ve seen “RSO” products in local discussions or online forums, they may bear little resemblance to what Simpson actually made. Many modern products labeled “RSO” are simply full-spectrum extracts in syringes—variable, untested, and potentially unsafe. Understanding what traditional RSO actually was helps you evaluate what’s being sold in Malta today.

OilWell Cannabis: Our Foundation

From McAllen to Malta: A Story of Survival and Innovation

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story doesn’t start in Houston—it starts in McAllen, Texas, one of the most economically challenged and dangerous border regions along the U.S.-Mexico border. The McAllen-Reynosa area, known as the Borderplex, is a place where poverty is pervasive, cartel violence is a daily reality, and opportunities are scarce outside of retail and healthcare.

Colin grew up learning to hustle in this environment—transporting items across the border, navigating dangers that most people never face. A lot of his best friends have been killed or are in prison because of the associated dangers. He’s faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite these challenges, Colin didn’t fall into the darkest paths. He chose cannabis—not as a recreational escape, but as a plant he believed could help people. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those risky ventures to building a legal, legitimate business.

Later, Colin became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines everything we do at OilWell.

Why Malta Should Care: Malta has its own communities shaped by economic hardship, border dynamics (though different from Texas), and systemic challenges. Whether you’re in Bormla, Żejtun, or Victoria, Gozo, you understand that real innovation often comes from people who’ve lived through real suffering. Colin’s background isn’t a corporate origin story—it’s a survival story that informs why we value accessibility, transparency, and integrity above all else.

Bentley: The Dog Who Started It All

Our company’s origin story begins with a dog named Bentley. Bentley was more than a pet—he was family, the companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD—through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience, but it was recreational. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo—dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis → Multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

For Malta’s Pet Owners: If you’re in Malta and you’ve faced a similar diagnosis for your beloved dog or cat—maybe a Maltese terrier, a Pharaoh hound, or a rescue from Gozo—you know that desperation. Bentley’s story is why we publish our CBD golden paste recipe for free:

CBD Golden Paste Recipe for Pets (Open-Source)

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (critical for absorption)
• CBD oil (dosage depends on pet size; consult a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until a thick paste forms (7-10 minutes)
2. Add coconut oil and black pepper, stir until thoroughly mixed
3. Allow to cool, then transfer to a jar and refrigerate for up to two weeks
4. Add CBD oil to each serving before administering

For Malta: This recipe uses ingredients available at any Maltese health food shop or grocery store. If you’re in Valletta, you can find organic turmeric and coconut oil at Arkadia Foodstore or Good Earth. The black pepper is crucial—it’s what makes the turmeric bioavailable. This is the exact formula that saved Bentley, and we’re giving it to Malta for free because that’s what OilWell stands for.

Our Personal Battle: PTSD and Benzo Withdrawal

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction—specifically Xanax. When he decided to break free, he did it cold turkey, a notoriously difficult and dangerous process, using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer Peace Gummies in vape form, which Colin personally uses to manage insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Reaching Malta’s Veterans and Trauma Survivors: Malta has a proud military history and a veteran community that deserves support. Whether you’re a veteran of international peacekeeping missions or someone dealing with trauma from any source, Colin’s personal experience with PTSD and benzo withdrawal makes our products relevant to your journey. We understand what it’s like when the conventional system fails you.

Mainstream Media Recognition: Seven ABC13 Features

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin and OilWell in seven comprehensive news segments. Five different reporters sought us out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

What This Means for Malta: When a major-market ABC affiliate repeatedly selects one company as its primary expert, it means that company has earned credibility through consistency, expertise, and community action. These weren’t paid advertisements—they were editorial decisions made by journalists covering business, law, medicine, community health, and politics. For Maltese readers, this is independently verified proof that OilWell operates with a level of transparency and integrity that most cannabis companies cannot match.

Here’s what ABC13 documented:

September 15, 2019 — “Texas CBD businesses booming”
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote from 2019 is the seed of everything we would become. It captures why we publish our formulas, why we cite research, and why we refuse to make unsupported claims.

March 22, 2021 — “Entrepreneur creates direct-to-consumer business”
Colin’s therapy framing: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 — “What is Delta-8 THC”
Steve Campion’s exchange:
Campion: “Why would someone want to smoke that?”
Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This uncensored honesty on mainstream television—ABC13 aired the expletive—demonstrates our commitment to telling the truth even when it’s uncomfortable.

August 20, 2021 — “Houston CBD shop giving away free products for COVID vaccine”
We gave away 1,000 caviar pre-rolls (approximately $35,000 in product) to encourage COVID vaccination. We coordinated with the City of Houston, with no political agenda, because community health matters more than profit.

October 19, 2021 — “Texas ban over Delta-8”
When Texas reclassified Delta-8 as Schedule I overnight, we proactively removed all products from our shelves. Colin warned other operators who were unknowingly shipping what had become Schedule I narcotics: “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.” We absorbed a massive revenue loss to operate ethically.

October 7, 2022 — “Biden marijuana pardon”
This feature revealed Colin’s personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything. I would love to see people not get hurt for this anymore.” This personal stake makes every other quote more powerful. Colin isn’t an outsider profiting from cannabis—he’s someone who lived the consequences and built a legal business to prove the industry could operate with integrity.

April 21, 2023 — “Marijuana industry getting creative”
Colin’s Renaissance framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

For Malta, this media record proves that OilWell has been vetted by independent journalism over four years. When you read about our products, you’re not reading marketing copy—you’re reading about a company that major media trusts as an expert source.

The Science Behind Our Formulas

Evidence-Based Approach: What We Know vs. What We Don’t

We built this document using a formal evidence hierarchy: human clinical evidence first, then systematic reviews, then institutional summaries, then preclinical literature. Malta’s educated population—whether you’re a healthcare professional in Gozo, a researcher at the University of Malta, or simply someone who values scientific rigor—deserves this level of transparency.

Important for Malta: The cannabinoid evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and preclinical pharmacology. We never pretend otherwise.

Cannabinoid Profiles: The Seven Compounds in Our Formula

CBD (Cannabidiol) — 4,500mg in Sublingual Oil

Best Supported Evidence:

• Seizure disorders: Purified CBD has the clearest human evidence, with FDA approval for certain rare epilepsies [1][2]
• Anxiety: A 2024 systematic review of 316 participants found significant anxiolytic signal, though authors stress more trials are needed [3]
• Pain: A 2024 review found promising but heterogeneous results, with trial quality still limiting confidence [4]
• Sleep: A 2023 review found the literature methodologically weak, with few objective sleep assessments [5]

Safety Considerations:
A 2023 systematic review found real signals for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH also flags diarrhea, sleepiness, appetite changes, mood effects, and drug-drug interactions [1].

For Malta: If you’re in Malta dealing with chronic pain, anxiety, or sleep issues—perhaps as an alternative to benzodiazepines or opioids—CBD is the best-studied non-intoxicating option. But even here, strong evidence is concentrated in specific indications rather than broad wellness claims.

CBG (Cannabigerol) — 3,000mg in Sublingual Oil

Evidence Profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to major cannabinoids, interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling—mechanistically interesting but not yet clinically established [7].

Research Areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses [7][8].

Caution: A 2021 review explicitly notes CBG is being sold commercially while the evidence base remains thin [7].

For Malta: CBG is a promising minor cannabinoid with limited clinical validation. We include it at substantial levels because the preclinical science is compelling, but we’re transparent about the evidence gap.

Delta-8 THC — 6,000mg in Sublingual Oil

Evidence Profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].

Comparative Pharmacology: A 2022 review concluded delta-8 and delta-9 THC have broadly similar pharmacokinetic behavior. Delta-8 is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9, likely due to weaker CB1 affinity [9].

Public Health Concerns: A 2023 scoping review found the evidence base dominated by animal studies, product chemistry, and public-health concerns rather than strong human trials, with reports of adverse consequences [10].

Manufacturing Context: Commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which raises product-byproduct and lab-testing concerns [11].

For Malta: Delta-8 THC is psychoactive and should be treated as a THC analogue with real pharmacologic activity but incomplete human safety characterization. Our product contains substantial delta-8—6,000 mg—making it significantly more potent than typical hemp products sold in Malta.

THCa (Tetrahydrocannabinolic Acid) — 1,500mg in Sublingual Oil

Evidence Profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].

What It Is: THCa is the acidic precursor of THC and may represent a large share of THC-related content in raw plant material. The key issue is that THCa decarboxylates into THC during heating and can change over time during storage and processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects, but this distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].

Research Status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

For Malta: THCa is our product’s “killer feature.” You can use it raw (non-psychoactive) for daytime anti-inflammatory benefits, or decarboxylate it at home into ~1,315 mg of delta-9 THC for full psychoactive potency—legally, because the conversion happens after purchase. This gives Maltese patients control that traditional RSO never offered.

Delta-9 THC — 90mg in Sublingual Oil

Evidence Profile: Strongest human evidence of the psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].

Best Supported Uses: NCCIH identifies relevance to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some MS/pain-related outcomes [1].

Pain Evidence: A 2022 systematic review found high-THC products may provide short-term pain benefit but increased dizziness, sedation, nausea, and treatment discontinuation [13].

Mental Health Risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression [15].

For Malta: Delta-9 THC has legitimate therapeutic relevance but carries clear intoxication, psychiatric, and dose-related safety liabilities. Our formula contains only 90 mg total—3 mg/mL—dramatically lower than traditional RSO’s 600-900 mg/day. This reflects modern safety consciousness while preserving therapeutic potential.

CBN (Cannabinol) — 750mg in Sublingual Oil

Evidence Profile: Weak human evidence; marketing has clearly moved ahead of the data [12][16][17].

Sleep Claims: CBN is widely marketed for sleep, but a 2021 review screened 99 human-study abstracts and found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16].

Broader Sleep Literature: A 2024 review concluded cannabinoid sleep research still doesn’t match real-world use scale, with need for better-designed, adequately powered trials [17].

For Malta: CBN is one of the clearest examples where cultural reputation exceeds clinical evidence. We include 750 mg (25 mg/mL) because our customers report sleep benefits, and we’re transparent about the evidence gap and the fact that the product is not intended to diagnose, treat, cure, or prevent disease.

CBC (Cannabichromene) — 750mg in Sublingual Oil

Evidence Profile: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19].

Pharmacology: A 2024 review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior, highlighting antinociceptive, antibacterial, and anti-seizure areas as interesting research targets [18].

Safety Caveat: The 2024 CBC review explicitly notes over-the-counter CBC products are being sold despite little evidence establishing clinical efficacy or safety [18].

For Malta: CBC belongs in the category of scientifically credible minor cannabinoids deserving more research, not already-validated clinical actives. We’re transparent about its investigational status.

Terpene Profiles: The Seven Aromatic Compounds

Terpenes need even stricter interpretation than cannabinoids. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. A 2024 entourage-effect review makes this clear: terpene bioactivity is plausible but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene — Citrus-Bright

Evidence: Largely review and preclinical [20]-[22]. A 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, and immune-modulatory possibilities, but most claims come from nonhuman literature [21].

Safety Note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing [22].

Malta Connection: If you’re in Malta, you’re surrounded by citrus—lemons, oranges, the Mediterranean air. You know the bright, uplifting aroma of limonene from everyday life. We include it for that sensory familiarity and its plausible mood-supporting properties.

Myrcene

Evidence: Mostly preclinical, very limited human evidence [20][23]. A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties but explicitly states human studies are lacking [23].

Malta Connection: Myrcene is found in mangoes, thyme, and lemongrass—flavors familiar to Maltese palates. The claim that myrcene causes “couch-lock” is stronger than current human evidence supports.

Caryophyllene (β-caryophyllene) — Pepper/Spice

Evidence: Among the most mechanistically interesting terpenes because it acts as a selective CB2 receptor agonist [24]. A 2021 review discusses anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, and gastroprotective actions, but human clinical confirmation remains limited [24].

Malta Connection: Black pepper is universal, including in Maltese kitchens. Caryophyllene’s CB2 agonism makes it especially relevant when discussing cannabis pharmacology rather than just aroma.

Pinene — Forest-Fresh

Evidence: Promising preclinical literature, weak human confirmation [20][25]. A 2021 review found antioxidant, anti-inflammatory, and neuroprotective signals justifying future study, but emphasized lack of well-designed clinical trials [25].

Malta Connection: Malta’s pine forests in places like Buskett Gardens give you the fresh pinene aroma. While claims about memory enhancement remain exploratory, the sensory connection is real for Maltese nature lovers.

Linalool — Floral, Lavender

Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]. A 2021 brain-health review found enough signal to justify continued investigation in neurological and psychiatric contexts [25].

Safety Note: Oxidized linalool hydroperoxides are recognized allergens [22].

Malta Connection: Lavender grows beautifully in Malta’s Mediterranean climate. The calming aroma of linalool is familiar whether you’re in a Maltese garden or using essential oils at home.

Humulene — Earthy, Woody

Evidence: Translationally interesting but early [20][27]. A 2024 scoping review of 340 articles found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties [27].

Malta Connection: The earthy aroma connects to Malta’s agricultural heritage—olive groves, vineyards, and herb gardens.

Terpinolene — Piney, Fruity, Sparkling

Evidence: One of the least clinically characterized terpenes [20][28]. A 2021 review screened 2,449 records and concluded the evidence base is dominated by in silico, in vitro, and animal studies [28].

Malta Connection: Terpinolene’s complex aroma profile adds brightness to our product’s sensory experience—something Maltese consumers who appreciate quality craftsmanship will notice.

Our RSO Formulas: Complete Transparency

RSO Sublingual Oil — $129.99

Cannabinoid	Amount (mg)	% of Total
CBD	4,500	27.1%
CBG	3,000	18.1%
Delta-8 THC	6,000	36.2%
THCa	1,500	9.0%
Delta-9 THC	90	0.5%
CBN	750	4.5%
CBC	750	4.5%
Total	16,590mg	100%

Additional Specifications:

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle (1 fl oz)
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper with 0.1mL increments
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximate doses per bottle: 40-60 (depending on serving size)

For Malta: This is the most comprehensive multi-cannabinoid RSO formula available. At 553mg/mL, it’s exceptionally concentrated. The graduated dropper allows precise dosing—crucial for Maltese patients who need to titrate carefully. The organic MCT oil base provides clean, consistent absorption.

RSO Vape Cartridge — $49.99

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

Additional Specifications:

• Live Terpenes: 5%+
• Format: 1-gram cartridge
• Total cannabinoids: 900mg+
• Thread: 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Auto-decarboxylation: Instantly converts THCa to delta-9 THC at 400-450°F

For Malta: The vape format is ideal for breakthrough pain, acute anxiety, or nausea—situations where Maltese patients need immediate relief. The 510-thread compatibility means it works with standard batteries available at vape shops across Malta.

How Our Formula Diverges from Traditional RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by heat	Live terpenes at 5% with defined profile
Standardization	None—every batch different	Lab-tested with mg/mL targets (553mg/mL)
Lab testing	Not performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate syringe-based	Measured per 0.1mL with known content
Product formats	Single thick oil only	Sublingual oil + vape cartridge
THCa preservation	No—fully decarboxylated	Yes—1,500mg as separate ingredient
Delta-9 THC dominance	60-90% of cannabinoids	Only 90mg total (0.5% of formula)
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why This Matters in Malta: Traditional RSO was crude, variable, and potentially unsafe. Our formula represents the evolution that Malta’s discerning consumers deserve—precision, safety, and transparency.

The Malta-Unique Advantage: Patient-Controlled Potency

Our formula gives Maltese customers three distinct usage options:

Option 1 — Raw (Non-Psychoactive): Use the oil as-is. All 1,500mg THCa stays acidic, producing zero psychoactive effects. Ideal for Maltese professionals who need daytime relief without impairment—doctors, lawyers, teachers, business owners who must remain sharp.

Option 2 — Fully Activated (Home Decarboxylation): Heat the oil at 260°F (125°C) for 45-60 minutes. This converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with the existing 90mg delta-9, you get ~1,405mg total delta-9 THC—potency comparable to traditional illegal RSO, entirely at your discretion after legal purchase.

Option 3 — Partial Activation: Transfer a controlled portion (e.g., 5mL) into a separate oven-safe container, decarboxylate only that portion, and preserve the rest raw. This allows you to maintain both a daytime non-psychoactive supply and a nighttime activated supply from the same bottle.

Conversion Chemistry: THCa (MW 358.47 g/mol) converts at a ratio of 1mg THCa = 0.877mg delta-9 THC, reflecting CO₂ loss during decarboxylation.

For Malta: This patient-controlled potency is revolutionary. Malta’s cannabis laws may be restrictive (medical access only, limited qualifying conditions). Our product is Farm Bill compliant at purchase—less than 0.3% delta-9 THC—making it legally accessible. The choice to activate is yours, made in private, after legal acquisition. This respects both Maltese law and patient autonomy.

Legal Framework: How Malta Residents Can Access Our Products

Farm Bill Compliance and International Shipping

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level in the United States. This is the foundation of our RSO product design.

Our sublingual oil contains only 90mg delta-9 THC in the entire 30mL bottle—3mg/mL—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under U.S. federal law and in most states.

International Shipping to Malta: We ship worldwide, including to Malta. Because our product contains less than 0.3% delta-9 THC at point of sale, it meets the definition of a hemp-derived product and is shippable to jurisdictions with compatible hemp laws.

Important Legal Notice: THCa converts to delta-9 THC when heated. Maltese customers are responsible for understanding and complying with local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

For Malta Specifically: Malta legalized medical cannabis in 2018 and recreational cannabis in 2021 (the first EU country to do so). However, access remains limited, products are expensive, and many patients prefer to source from reputable international providers. Our Farm Bill-compliant products can legally enter Malta as hemp-derived supplements, provided they meet local import requirements. We include complete COAs to facilitate customs clearance.

Customer Responsibility Disclaimer

Age Requirement: 21+ for all RSO products

FDA Disclaimer: These products have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a healthcare provider before use, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns.

Safety Warnings: May cause drowsiness or impairment. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Keep out of reach of children. Store in a cool, dry place away from heat and light to prevent THCa decarboxylation if you wish to preserve the raw form.

Legal Responsibility: Buyer assumes all responsibility for compliance with local Maltese laws. OilWell assumes no legal responsibility for customer’s use or decarboxylation decisions. Void where prohibited by law.

Delivery and Accessibility for Malta

International Shipping to Malta

We ship to Malta via USPS Priority Mail International (6-10 business days) or FedEx International (3-5 business days). All packages include:

• Complete Certificate of Analysis (COA) for customs
• Detailed product description and receipt
• Discreet packaging with no cannabis branding visible
• Tracking number provided
• Temperature-stable packaging for Mediterranean climate

Shipping Costs: Flat-rate international shipping applies. Contact us at [email protected] or (832) 416-2816 for current rates to Malta.

Customs Considerations: Malta’s customs authorities may inspect packages. Our complete documentation ensures transparency. We cannot guarantee delivery times due to customs processing, but we’ve successfully delivered to Malta and other EU countries.

Payment: International customers can pay via credit card or cryptocurrency. All transactions are processed securely.

Why International Access Matters for Malta

In Malta, medical cannabis is legal but access can be challenging. The limited number of pharmacies authorized to dispense, the requirement for specific prescriptions, and the high cost create barriers. Our international shipping program means that Maltese patients who cannot access or afford local medical cannabis products have a legal, transparent, high-quality alternative.

Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Mdina, a chronic pain sufferer in St. Julian’s, or a veteran in Paola can now potentially access the same clinical-strength multi-cannabinoid RSO formula that Houston residents receive via same-day delivery. We’ve built a product that can move across borders legally, completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.

Condition-Specific Usage Context for Malta

Critical Disclaimer: These usage contexts are informed by cannabinoid research cited in our General Knowledge section. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT a substitute for professional medical care. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products. Do not operate vehicles or machinery while under the influence.

For Malta: We encourage you to discuss any cannabinoid use with your Maltese doctor, whether you’re receiving care at Mater Dei Hospital, a private clinic in Sliema, or through Malta’s national health service. Integrative medicine practitioners in Malta may be particularly open to these discussions.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)
• Evidence: Delta-8 antiemetic [9], delta-9 nausea/vomiting [1][13], CBD anxiolytic buffering [3]

For Malta: If you’re undergoing chemotherapy at Sir Paul Boffa Hospital or a private oncology center, cannabinoid therapy may help manage side effects. Our vape format is particularly valuable for acute nausea that strikes suddenly.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5mL raw sublingual—anti-inflammatory without psychoactive impairment
• Nighttime: 0.5-1.0mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD pain [4], delta-9 THC pain [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

For Malta: Chronic pain affects many Maltese residents, especially those in physically demanding jobs or dealing with age-related conditions. Our raw daytime option allows you to function without impairment while receiving anti-inflammatory support.

Sleep Support

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL: Delivers 50mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0mL: Delivers 25mg CBN—above the 20mg threshold associated with reduced sleep disturbance
• Evidence: CBN sleep [16][17], cannabis and sleep review literature

For Malta: Sleep disorders are common in Malta’s fast-paced urban areas. Our CBN content is substantial, though we acknowledge the evidence base remains limited compared to marketing claims.

Anxiety and Stress

• Daytime functional relief: 0.3mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0mL sublingual—full profile including CBN for sleep architecture
• Evidence: CBD anxiety [3], CBG pharmacology [7][8], limonene entourage evidence [20]

For Malta: Whether you’re dealing with work stress in Malta’s competitive business environment or anxiety from health concerns, our daytime raw option provides support without psychoactive effects.

General Titration Principle for Malta

Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Malta-Specific Considerations: Mediterranean diets, local medications, and individual genetics all affect cannabinoid metabolism. Maltese patients should be especially conservative if new to cannabinoids.

Competitive Comparison: Why OilWell for Malta?

OilWell RSO vs. Malta Medical Cannabis Program

Dimension	Malta Medical Cannabis	OilWell RSO
Cannabinoid options	Limited to approved products	7 cannabinoids at precise ratios
Access requirements	Specific doctor prescription, qualifying conditions	Age 21+, no medical card required
THC options	Restricted doses	Patient-controlled (raw to 1,405mg activated)
Terpene content	Variable, often minimal	5% live terpenes with defined profile
Lab testing	Required but results may not be public	Full COAs publicly available on request
Price	High (regulated market)	$129.99 for 30mL (16,590mg total cannabinoids)
Delivery	Pharmacy pickup required	Direct shipping to Malta
International access	Not available	Worldwide shipping available

For Malta: Malta’s medical cannabis program, while progressive within the EU, remains restrictive. Our product offers cannabinoid diversity, patient control, and direct access that Malta’s program doesn’t match.

OilWell RSO vs. European CBD-Only Products

Dimension	Typical EU CBD Oil	OilWell RSO
Total cannabinoids	500-2,000mg	16,590mg
CBD content	500-2,000mg	4,500mg
CBG content	0-50mg	3,000mg
CBN content	0-20mg	750mg
Delta-8 THC	0mg	6,000mg
THCa	Minimal	1,500mg
Delta-9 THC	<0.2% (EU limit)	90mg (<0.3% at sale, convertible to 1,405mg)
Psychoactive option	No	Yes—patient controlled
Terpenes	Often minimal	5% live terpenes
Price	€50-120	€120 equivalent for superior cannabinoid diversity

For Malta: European CBD oils are often single-cannabinoid products with limited therapeutic potential. Our formula delivers seven cannabinoids at therapeutic levels, plus terpenes, for comprehensive support.

Open-Source Philosophy: Our Gift to Malta

Why We Publish Everything

Rick Simpson gave his oil away for free and taught people how to make it. He never patented his method. That ethos is fundamental to the RSO movement.

We adapted that philosophy for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

The Complete Malta RSO Recipe

If you’re in Malta and cannot afford our $129.99 product—or if you simply want to make your own—you have everything you need in this document. Source hemp-derived cannabinoid distillates and isolates from reputable European suppliers (ensure they provide COAs), mix according to our exact specifications, and create your own version.

We’d rather you have safe access than no access at all. That’s the promise Colin made in 2019 on ABC13, and it’s the promise we extend to Malta today.

Final Thoughts: A Message to Malta

Malta, we see you. We see your beautiful coastlines, your resilient people, your growing curiosity about cannabinoid medicine. We see the cancer patients at Sir Anthony Mamo Oncology Centre searching for options. We see the veterans in Valletta struggling with PTSD. We see the chronic pain sufferers in Gozo who’ve tried everything else.

We’ve been where you are. We’ve faced the desperation, the failed treatments, the hope that something better might exist. Bentley’s story taught us that cannabinoids can do things pharmaceuticals cannot. Colin’s personal battle with benzo withdrawal taught us that these plant compounds can literally save lives.

What we’re offering Malta isn’t just a product. It’s a philosophy:

• Accessibility over gatekeeping — No medical card required, international shipping available
• Patient-controlled potency — You decide whether to use raw or activated
• Open-source formulas — If you can’t afford it, make it yourself
• Evidence-informed honesty — We tell you what we know, what we don’t, and what we’re still learning

From Houston to Malta, from Bentley’s miracle to your own journey, we’re here to provide the best possible version of RSO education so you can give it a fair shot and decide if it’s right or wrong for you.

Contact Us:
Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/
Instagram: @oilwellcbd

We ship to Malta. We support Malta. We welcome Malta into the OilWell community.

Disclaimer: This content is for educational and informational purposes only. These products have not been evaluated by the Food and Drug Administration or any Maltese regulatory authority. They are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products. Do not operate vehicles or machinery while under the influence. Keep out of reach of children. Buyer assumes all responsibility for compliance with Malta law. OilWell assumes no legal responsibility for customer’s use or decarboxylation decisions. Individual results may vary. This information does not constitute medical advice for Maltese residents.

---